A5039305143- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Eosinophilic Disorders and Syndromes
- Multiple Myeloma Research and Treatments
- T-cell and B-cell Immunology
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Immune Cell Function and Interaction
- Lymphoma Diagnosis and Treatment
- Hemoglobinopathies and Related Disorders
- Renal Transplantation Outcomes and Treatments
- Cytomegalovirus and herpesvirus research
- Immunotherapy and Immune Responses
- PI3K/AKT/mTOR signaling in cancer
- Prenatal Screening and Diagnostics
- RNA modifications and cancer
- Venous Thromboembolism Diagnosis and Management
- Neutropenia and Cancer Infections
- Bone health and treatments
- Polyomavirus and related diseases
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Oral health in cancer treatment
Imperial College London
2015-2024
Hammersmith Hospital
2015-2024
Anthony Nolan
2016-2024
University College London
2017-2024
The Royal Free Hospital
2017-2024
Imperial College Healthcare NHS Trust
2010-2023
First Pavlov State Medical University of St. Petersburg
2019
Imperial Valley College
2019
British Society for Haematology
2010-2014
National Health Service
2012
There is a considerable variability in the level of molecular responses achieved with imatinib therapy patients chronic myeloid leukemia (CML). These differences could result from variable adherence.Eighty-seven chronic-phase CML treated 400 mg/d for median 59.7 months (range, 25 to 104 months) who had complete cytogenetic response adherence monitored during 3-month period by using microelectronic monitoring device. Adherence was correlated levels response. Other factors that influence...
Purpose Imatinib is remarkably effective in treating newly diagnosed patients with chronic myeloid leukemia (CML) phase (CP). To date, most of the available data come from a single multicenter study which some were censored for diverse reasons. Here, we report our experience at institution setting where all events recorded. Patients and Methods A total 204 consecutive adult CML CP received imatinib June 2000 until August 2006. Response (hematologic, cytogenetic, molecular), progression-free...
PURPOSE To compare outcomes of bone marrow transplants for leukemia from HLA-identical siblings, haploidentical HLA-mismatched relatives, and HLA-matched mismatched unrelated donors. PATIENTS A total 2,055 recipients allogeneic chronic myelogenous (CML), acute (AML), lymphoblastic (ALL) were entered onto the study. Transplants performed between 1985 1991 reported to International Bone Marrow Transplant Registry (IBMTR). Donors siblings (n = 1,224); relatives one 238) or two 102) HLA-A, -B,...
We studied BCR-ABL1 transcript levels in patients with chronic myeloid leukemia phase (CML-CP) at 3, 6, and 12 months after starting imatinib to identify molecular milestones that would predict for overall survival (OS) other outcomes more reliably than serial marrow cytogenetics.We analyzed 282 CML-CP who received 400 mg/d as first-line therapy followed by dasatinib or nilotinib if treatment failed. used a receiver operating characteristic curve the cutoffs best patient outcome. validated...
To determine major presenting features of chronic myeloid leukaemia (CML) in current practice, we have reviewed the records 430 patients with CML referred to Hammersmith Hospital for allogeneic bone marrow transplantation since 1981. Approximately 20% cases were diagnosed incidentally. Symptoms such as fatigue and weight loss associated greater degrees leucocytosis splenomegaly lower haemoglobin levels. Most bleeding had normal or elevated platelet counts, suggesting that dysfunction was...
Kinase domain (KD) mutations in the BCR-ABL gene are associated with resistance to imatinib chronic myeloid leukemia (CML) but their incidence and prognostic significance phase (CP) patients without unclear.We analyzed outcome for 319 CML-CP who were treated imatinib; 171 early CP (ECP) 148 late (LCP). Patients screened routinely using direct sequencing regardless of response status. The 5-year cumulative was 6.6% ECP 17% LCP patients.Of patients, 214 (67%) achieved complete cytogenetic...
Background In 2009 the declaration by World Health Organization of a global pandemic influenza-H1N1 virus led to vaccination campaign ensure protection for immunocompromised patients. The goal this study was determine efficacy H1N1 vaccine in patients with hematologic malignancies.Design and Methods We evaluated humoral cellular immune responses 97 adults malignancies compared these those 25 adult controls. Patients received two injections 21 days apart controls one dose. Antibody titers...
Abstract Resistance to 5-Fluoruracil (5-FU) has been linked elevated expression of the main target, thymidylate synthase (TYMS), which catalyses de novo pathway for production deoxythymidine monophosphate. The potent oncogenic forkhead box transcription factor, FOXM1 is regulated by E2F1 also controls TYMS. This study reveals a significant role in 5-FU resistance. Overexpression and knock-down studies colon cancer cells suggest importance TYMS regulation. ChIP global ChIP-seq data confirms...
HLA matching at an allelic-level resolution for volunteer unrelated donor (VUD) hematopoietic cell transplantation (HCT) results in improved survival and fewer post-transplant complications. Limitations typing technologies used the hyperpolymorphic genes have meant that variations outside of antigen recognition domain (ARD) not been previously characterized HCT. Our aim was to explore extent diversity ARD determine impact this on transplant outcome. Eight hundred ninety-one VUD-HCT donors...
This retrospective study by the European Society for Blood and Marrow Transplantation analyzed outcome of 2224 patients with myelofibrosis (MF) who underwent allogeneic stem cell transplantation (allo-SCT) between 2000 2014; 781 (35%) myeloablative conditioning (MAC) 1443 (65%) reduced-intensity (RIC). Median patient age was 52.9 years (range, 18 to 74 years) 57.5 21 76 in MAC RIC cohorts, respectively. Donor type similar: matched sibling donors (MAC, 317 [41%]; RIC, 552 [38%]) unrelated 464...
The role of serum macrophage inflammatory protein-1 alpha (MIP-1alpha) in bone disease and survival was evaluated 85 newly diagnosed multiple myeloma (MM) patients. MIP-1alpha elevated MM patients correlated with the extent disease, resorption markers levels soluble receptor activator nuclear factor-kappaB (RANK) ligand. also associated survival; 3-year probability 85% 44% for below above 48 pg/ml respectively (P = 0.021). This suggests that contributes to pathogenesis possibly tumour...
Dickkopf-1 (DKK-1) protein, a soluble inhibitor of Wnt signalling, has been implicated in the pathogenesis myeloma bone disease through suppression osteoblast differentiation. In this study, serum concentrations DKK-1 were measured 50 patients (32 at diagnosis and 18 before after autologous stem cell transplantation (ASCT), with monoclonal gammopathy undetermined significance (MGUS), 22 healthy controls. Serum levels increased MM compared MGUS (mean +/- SD: 67 54 ng/mL vs. 38 13 ng/mL; p =...